Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels


Kisim A., Atmaca H., ÇAKAR B. , KARABULUT B. , SEZGIN C., Uzunoglu S., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.138, ss.1155-1163, 2012 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 138 Konu: 7
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00432-012-1187-1
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.1155-1163

Özet

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and has been shown to induce extrinsic pathway of apoptosis in many types of cancer cells. AT-101, an (-)-enantiomer of gossypol, is a potent anticancer agent that is shown to be an inhibitor of Bcl-2/Bcl-XL. In this study, we searched whether pretreatment with either of these drugs would result in the enhancement of apoptosis through induction of death receptors and activation of mitochondrial pathways within breast cancer cells.